Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015

Corporate Breaking News

Home : Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015

Dec 12 2019	Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015
STOCKHOLM, Dec. 12, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB): On Monday the topline results were presented from the first study in the Phase 3 program for MOB-015, where the primary endpoint and the two key secondary endpoints were met. Since the results are somewhat contradictory...


Source:https://www.prnewswire.com:443/news-releases/moberg-pharma-comments-on-the-results-of-the-north-american-phase-3-study-with-mob-015-300973809.html

Related News
» Imani Lee Expands Its Language Services Work Throughout California » Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium